BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 12695659)

  • 1. Certainly no ARFterthought: oncogenic cooperation in ARF induction a key step in tumor suppression.
    Haupt Y
    Cell Cycle; 2003; 2(2):113-5. PubMed ID: 12695659
    [No Abstract]   [Full Text] [Related]  

  • 2. An Arf(GFP/GFP) reporter mouse reveals that the Arf tumor suppressor monitors latent oncogenic signals in vivo.
    Sherr CJ
    Cell Cycle; 2004 Mar; 3(3):239-40. PubMed ID: 14726696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ARF and ATM/ATR cooperate in p53-mediated apoptosis upon oncogenic stress.
    Pauklin S; Kristjuhan A; Maimets T; Jaks V
    Biochem Biophys Res Commun; 2005 Aug; 334(2):386-94. PubMed ID: 16004968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence.
    Zou X; Ray D; Aziyu A; Christov K; Boiko AD; Gudkov AV; Kiyokawa H
    Genes Dev; 2002 Nov; 16(22):2923-34. PubMed ID: 12435633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation.
    Lin AW; Lowe SW
    Proc Natl Acad Sci U S A; 2001 Apr; 98(9):5025-30. PubMed ID: 11309506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. E2F1 suppresses skin carcinogenesis via the ARF-p53 pathway.
    Russell JL; Weaks RL; Berton TR; Johnson DG
    Oncogene; 2006 Feb; 25(6):867-76. PubMed ID: 16205640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of ARF by oncogenic stress in mouse fibroblasts is independent of E2F1 and E2F2.
    Palmero I; Murga M; Zubiaga A; Serrano M
    Oncogene; 2002 May; 21(19):2939-47. PubMed ID: 12082524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development.
    Eischen CM; Alt JR; Wang P
    Oncogene; 2004 Nov; 23(55):8931-40. PubMed ID: 15467748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance of primary cultured mouse hepatic tumor cells to cellular senescence despite expression of p16(Ink4a), p19(Arf), p53, and p21(Waf1/Cip1).
    Obata M; Imamura E; Yoshida Y; Goto J; Kishibe K; Yasuda A; Ogawa K
    Mol Carcinog; 2001 Sep; 32(1):9-18. PubMed ID: 11568971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repression of the Arf tumor suppressor by E2F3 is required for normal cell cycle kinetics.
    Aslanian A; Iaquinta PJ; Verona R; Lees JA
    Genes Dev; 2004 Jun; 18(12):1413-22. PubMed ID: 15175242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The TRIP from ULF to ARF.
    Collado M; Serrano M
    Cancer Cell; 2010 Apr; 17(4):317-8. PubMed ID: 20385357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CARF binds to three members (ARF, p53, and HDM2) of the p53 tumor-suppressor pathway.
    Kamrul HM; Wadhwa R; Kaul SC
    Ann N Y Acad Sci; 2007 Apr; 1100():312-5. PubMed ID: 17460193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
    Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T
    Clin Cancer Res; 2003 Oct; 9(13):4884-90. PubMed ID: 14581362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ARF tumor suppression in the nucleolus.
    Maggi LB; Winkeler CL; Miceli AP; Apicelli AJ; Brady SN; Kuchenreuther MJ; Weber JD
    Biochim Biophys Acta; 2014 Jun; 1842(6):831-9. PubMed ID: 24525025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A senescence rescue screen identifies BCL6 as an inhibitor of anti-proliferative p19(ARF)-p53 signaling.
    Shvarts A; Brummelkamp TR; Scheeren F; Koh E; Daley GQ; Spits H; Bernards R
    Genes Dev; 2002 Mar; 16(6):681-6. PubMed ID: 11914273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defects in TGF-beta signaling overcome senescence of mouse keratinocytes expressing v-Ha-ras.
    Tremain R; Marko M; Kinnimulki V; Ueno H; Bottinger E; Glick A
    Oncogene; 2000 Mar; 19(13):1698-709. PubMed ID: 10763827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of p53 ubiquitination and nuclear export by MDM2 and ARF.
    Zhang Y; Xiong Y
    Cell Growth Differ; 2001 Apr; 12(4):175-86. PubMed ID: 11331246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual inactivation of RB and p53 pathways in RAS-induced melanomas.
    Bardeesy N; Bastian BC; Hezel A; Pinkel D; DePinho RA; Chin L
    Mol Cell Biol; 2001 Mar; 21(6):2144-53. PubMed ID: 11238948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benzo(a)pyrene-induced changes in p53 and related proteins in mouse skin.
    Serpi R; Vähäkangas K
    Pharmacol Toxicol; 2003 May; 92(5):242-5. PubMed ID: 12753412
    [No Abstract]   [Full Text] [Related]  

  • 20. p19Arf suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways.
    Kelly-Spratt KS; Gurley KE; Yasui Y; Kemp CJ
    PLoS Biol; 2004 Aug; 2(8):E242. PubMed ID: 15314658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.